Scientific Reports · 2019 · 41 citations · 41 references
Life SciencesCell BiologyPharmacologyAutophagyCell SignalingInnate ImmunityLipid MetabolismLipid RaftsLipophagyMacrophage BiologyMembrane MicrodomainsMitophagyAntileishmanial TreatmentAutophagy PathwayLeishmaniasis PathogenesisLipid Raft OrganizationMacrophage Inflammasome ActivationMembrane Lipid HomeostasisNlrp3 InflammasomeVisceral Leishmaniasis
Miltefosine is an FDA approved oral drug for treating cutaneous and visceral leishmaniasis. Leishmania is a flagellated protozoa, which infects and differentiates in macrophages. Here, we studied the effects of Miltefosine on macrophage's lipid homeostasis, autophagy, and NLRP3 inflammasome assembly/activity. Miltefosine treatment conferred multiple effects on macrophage lipid homeostasis leading to increased cholesterol release from cells, increased lipid-raft disruption, decreased phosphatidylserine (PS) flip from the cell-surface, and redistribution of phosphatidylinositol 4,5-bisphosphate (PIP2) from the plasma membrane to actin rich regions in the cells. Enhanced basal autophagy, lipophagy and mitophagy was observed in cells treated with Miltefosine vs. control. Miltefosine treated cells showed marked increased in phosphorylation of kinases involved in autophagy induction such as; Adenosine monophosphate-activated protein kinase (AMPK) and Unc-51 like autophagy activating kinase (ULK1). The Toll like receptor (TLR) signaling pathway was blunted by Miltefosine treatment, resulting in decreased TLR4 recruitment to cell-surface and ~75% reduction in LPS induced pro-IL-1β mRNA levels. Miltefosine reduced endotoxin-mediated mitochondrial reactive oxygen species and protected the mitochondrial membrane potential. Miltefosine treatment induced mitophagy and dampened NLRP3 inflammasome assembly. Collectively, our data shows that Miltefosine induced ABCA1 mediated cholesterol release, induced AMPK phosphorylation and mitophagy, while dampening NLRP3 inflammasome assembly and IL-1β release.
41
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
Paul M. Ridker, Tom Thurén, Jean MacFadyen et al. · New England Journal of Medicine · 2017 · 9.1K citations · Full text
AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1
Joungmok Kim, Mondira Kundu, Benoı̂t Viollet et al. · Nature Cell Biology · 2011 · 7K citations · Full text
A role for mitochondria in NLRP3 inflammasome activation
Rongbin Zhou, Amir S. Yazdi, Philippe Menu et al. · Nature · 2010 · 5.4K citations
NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals
Peter Duewell, Hajime Kono, Katey J. Rayner et al. · Nature · 2010 · 3.9K citations · Full text
Caspase-11 cleaves gasdermin D for non-canonical inflammasome signalling
Nobuhiko Kayagaki, Irma B. Stowe, Bettina L. Lee et al. · Nature · 2015 · 3.7K citations